PMID- 32048267
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 72
IP  - 4
DP  - 2020 Aug
TI  - Inhibitory effects of orientin in mast cell-mediated allergic inflammation.
PG  - 1002-1010
LID - 10.1007/s43440-019-00048-3 [doi]
AB  - BACKGROUND: Mast cells are immune effector cells mediating allergic inflammation 
      by the secretion of inflammatory mediators such as histamine and pro-inflammatory 
      cytokines. Orientin is a naturally occurring bioactive flavonoid that possesses 
      diverse biological properties, including anti-inflammation, anti-oxidative, 
      anti-tumor, and cardio protection. The objective of this study was to rule out 
      the effectiveness of orientin in mast cell-mediated allergic inflammation. 
      METHODS: In this study, in vitro effects of orientin were evaluated in RBL-2H3, 
      mouse bone marrow-derived mast cells, rat peritoneal mast cells, and in vivo 
      effects were evaluated by inducing passive cutaneous anaphylaxis (PCA) in 
      Imprinting Control Region (ICR) mice. RESULTS: Findings show that orientin 
      suppressed the immunoglobulin E (IgE)-mediated mast cell degranulation by 
      reducing intracellular calcium level in a concentration-dependent manner. 
      Orientin suppressed the secretion of pro-inflammatory cytokines in mast cells. 
      This inhibitory effects of orientin was through inhibition of FcepsilonRI-mediated 
      signaling proteins. In addition, oral administration of orientin suppressed the 
      IgE-mediated PCA reactions in a dose-dependent manner, which was evidenced by 
      reduced Evan's blue pigmentation and ear swelling. CONCLUSIONS: Based on these 
      findings, we suggest that orientin might have potential to alleviate allergic 
      reaction and mast cell-mediated allergic disease.
FAU - Dhakal, Hima
AU  - Dhakal H
AD  - Cell and Matrix Research Institute, Department of Pharmacology, School of 
      Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu, 
      41944, Republic of Korea.
FAU - Lee, Soyoung
AU  - Lee S
AD  - Immunoregulatory Materials Research Center, Korea Research Institute of 
      Bioscience and Biotechnology, Jeongeup, Republic of Korea.
FAU - Choi, Jin Kyeong
AU  - Choi JK
AD  - Molecular Immunology Section, Laboratory of Immunology, National Eye Institute, 
      National Institutes of Health, Bethesda, MD, USA.
FAU - Kwon, Taeg Kyu
AU  - Kwon TK
AD  - Department of Immunology, School of Medicine, Keimyung University, Daegu, 
      Republic of Korea.
FAU - Khang, Dongwoo
AU  - Khang D
AD  - Department of Physiology, School of Medicine, Gachon University, 191, 
      Hambangmoe-ro, Yeonsu-gu, Incheon, Republic of Korea. dkhang@gachon.ac.kr.
FAU - Kim, Sang-Hyun
AU  - Kim SH
AD  - Cell and Matrix Research Institute, Department of Pharmacology, School of 
      Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu, 
      41944, Republic of Korea. shkim72@knu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20200124
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Flavonoids)
RN  - 0 (Glucosides)
RN  - 0 (Inflammation Mediators)
RN  - IAX93XCW6C (orientin)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/pharmacology/*therapeutic use
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Flavonoids/pharmacology/*therapeutic use
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Hypersensitivity/immunology/metabolism/*prevention & control
MH  - Inflammation Mediators/*antagonists & inhibitors/immunology/metabolism
MH  - Male
MH  - Mast Cells/*drug effects/immunology/metabolism
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Allergic inflammation
OT  - Histamine
OT  - Mast cell
OT  - Orientin
OT  - Passive cutaneous anaphylaxis
EDAT- 2020/02/13 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/02/13 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2019/12/11 00:00 [accepted]
PHST- 2019/12/03 00:00 [revised]
PHST- 2020/02/13 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2020/02/13 06:00 [entrez]
AID - 10.1007/s43440-019-00048-3 [pii]
AID - 10.1007/s43440-019-00048-3 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2020 Aug;72(4):1002-1010. doi: 10.1007/s43440-019-00048-3. Epub 
      2020 Jan 24.